A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT ID: NCT04556383

Last Updated: 2023-08-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

236 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-19

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 2-part study, comprising of a 36-week placebo-controlled period (PCP) and a 24-week open-label extension (OLE) period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to background UC therapy of 5-aminosalicylate (5-ASA) with or without systemic steroids.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Subjects, investigators and site personnel, and the Sponsor will be blinded to individual subject treatment assignments.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCP Placebo

PCP Placebo for oral administration for 36 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral tablet

PCP GB004 480 mg QD

PCP GB004 480 mg QD for oral administration for 36 weeks

Group Type EXPERIMENTAL

GB004

Intervention Type DRUG

oral tablet

PCP GB004 480 mg BID

PCP GB004 480 mg BID for oral administration for 36 weeks

Group Type EXPERIMENTAL

GB004

Intervention Type DRUG

oral tablet

Open-Label Extension (OLE) GB004 480 mg BID

OLE GB004 480 mg BID for oral administration for 24 weeks

Group Type EXPERIMENTAL

GB004

Intervention Type DRUG

oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GB004

oral tablet

Intervention Type DRUG

Placebo

oral tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult male and female subjects aged ≥ 18 years at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures.
* UC diagnosed at least 3 months prior to first dose of investigational product (IP) on Day 1.
* Currently receiving treatment for UC, on a stable dose for at least 2 weeks prior to flexible sigmoidoscopy or colonoscopy, with oral 5-ASA (eg, mesalamine, sulfasalazine) alone or with one of the following oral treatments:

1. prednisone ≤ 20 mg/day or equivalent or
2. beclomethasone ≤ 5 mg/day or
3. budesonide or budesonide multi-matrix (MMX) of ≤ 9 mg/day

Exclusion Criteria

* Prior approved biologic therapy used for the treatment of UC.
* Diagnosis of Crohn's disease, indeterminate colitis, or pouchitis, or presence of bacterial or parasitic infection.
* Tofacitinib, oral cyclosporine, sirolimus or mycophenolate mofetil within 8 weeks of Day 1.
* Azathioprine, or 6-mercaptopurine within 1 day of Day 1.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GB004, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

B G Clinical Research, Inc.

Encinitas, California, United States

Site Status

Gastro Care Institute

Lancaster, California, United States

Site Status

Texas Digestive Disease Consultants

Baton Rouge, Louisiana, United States

Site Status

Gastroenterology Clinic of Acadiana

Lafayette, Louisiana, United States

Site Status

Delta Research Partners

Monroe, Louisiana, United States

Site Status

Huron Gastroenterology Associates

Ypsilanti, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Las Vegas Medical Research

Las Vegas, Nevada, United States

Site Status

Freehold Endoscopy Associates, LLC d/b/a/ Endoscopy Center of Monmouth County

Freehold, New Jersey, United States

Site Status

Great Lakes Gastroenterology Research, LLC

Mentor, Ohio, United States

Site Status

Texas Digestive Disease Consultant

Southlake, Texas, United States

Site Status

Washington Gastroenterology, PLLC

Bellevue, Washington, United States

Site Status

Washington Gastroenterology, PLCC

Tacoma, Washington, United States

Site Status

JSC Infectious Diseases, AIDS and Clinical Immunology Research Center

Tbilisi, , Georgia

Site Status

LTD Aversi Clinic

Tbilisi, , Georgia

Site Status

LTD Central University Clinic After Academic N. Kipshidze

Tbilisi, , Georgia

Site Status

LTD Coloproctological Center of Georgia

Tbilisi, , Georgia

Site Status

Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LTD

Tbilisi, , Georgia

Site Status

PMSI Republican Clinical Hospital "Timofei Mosneaga"

Chisinau, , Moldova

Site Status

CLINSANTE Clinical Research Center Civil Law Partnership Ewa Galczak-Nowak, Malgorzata Trzaska

Bydgoszcz, , Poland

Site Status

St. John Paul 2 Municipal Hospital in Elblag, Department of Internal Medicine

Elblag, , Poland

Site Status

Clinical Research Center of Karkonosze - Lexmedica Limited Liability Company, KCBK - LEXMEDICA

Jelenia Góra, , Poland

Site Status

Professor K. Gibinski University Clinical Centre of the Medical University of Silesia in Katowice

Katowice, , Poland

Site Status

"LANDA" Katarzyna Agata Landa, Landa" Specialist Doctor's Offices

Krakow, , Poland

Site Status

Medicome Limited Liability Company, Oswiecim Clinical Trial Centre

Oświęcim, , Poland

Site Status

Marek Horynski, MD, Ph.D. Individual Specialist Medical Practice [Specjialistyczna Praktyka Lekarska Dr med. Marek Horynski]

Sopot, , Poland

Site Status

"NOWE ZDROWIE-CK" Kieltucki and Partners General Partnership, NOWE ZDROWIE-CK

Staszów, , Poland

Site Status

"Gastromed" Torun Gastrology Centre [Torunskie Centrum Gastrologiczne "Gastromed"]

Torun, , Poland

Site Status

EB GROUP Limited Liability Company, MDM Health Centre

Warsaw, , Poland

Site Status

WIP Warsaw IBD Point Profesor Kierkus

Warsaw, , Poland

Site Status

Reuma Park Clinic Limited Liability Company Limited Partnership, Reuma Park Medical Center

Warsaw, , Poland

Site Status

VIVAMED Non-Public Healthcare Facility

Warsaw, , Poland

Site Status

Clinical Research Center Piotr Napora Medical Doctors Professional Partnership

Wroclaw, , Poland

Site Status

Colentina Clinical Hospital

Bucharest, , Romania

Site Status

Limited Liability Company Joint Venture Diagnostic Center "Biotherm"

Barnaul, , Russia

Site Status

"Myod" Ltd.

Bataysk, , Russia

Site Status

Federal Siberian Research Clinical Center under the Federal Medical Biological Agency

Krasnoyarsk, , Russia

Site Status

Moscow State-Funded Healthcare Institution City Clinical Hospital n.a. V.M. Buyanov under Moscow Healthcare Department

Moscow, , Russia

Site Status

Medical Center SibNovoMed, Limited Liability Company

Novosibirsk, , Russia

Site Status

Novosibirskiy Gastrocenter, LLC

Novosibirsk, , Russia

Site Status

Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences

Novosibirsk, , Russia

Site Status

Medical Diagnostic Center, Limited Liability Company

Orenburg, , Russia

Site Status

Penza Regional Clinical Hospital named after N.N. Burdenko

Penza, , Russia

Site Status

Clinic UZI 4D, Limited Liability Company

Pyatigorsk, , Russia

Site Status

S.M. Kirov Miltiary Medical Academy

Saint Petersburg, , Russia

Site Status

St. Petersburg State-Funded Healthcare Institution: City Outpatient Care Unit No. 38

Saint Petersburg, , Russia

Site Status

Consultation and Diagnostics Center and Outpatient Care Unit under the Department of Presidential Affairs

Saint Petersburg, , Russia

Site Status

Regional State-Funded Healthcare Institution: Novgorod Regional Clinic Hospital

Veliky Novgorod, , Russia

Site Status

Clinical Hospital Center "Dr Dragisa Misovic Dedinje'' local lab

Belgrade, , Serbia

Site Status

Clinical Hospital Center "Dr Dragisa Misovic Dedinje''

Belgrade, , Serbia

Site Status

Clinical Hospital Center Zemun

Belgrade, , Serbia

Site Status

Zvezdara University Medical Center-local lab

Belgrade, , Serbia

Site Status

Clinical Center Kragujevac

Kragujevac, , Serbia

Site Status

General Hospital "Djordje Joanovic"

Zrenjanin, , Serbia

Site Status

Inje University Heaundae Paik Hospital

Busan, , South Korea

Site Status

Dong-A University Hospital

Busan, , South Korea

Site Status

Kyungpook National University Chilgok Hospital

Daegu, , South Korea

Site Status

Communal Nonprofit Enterprise "Cherkasy Regional Hospital of Cherkasy Oblast Council"

Cherkasy, , Ukraine

Site Status

Regional Communal Noncommercial Enterprise "Chernivtsi Regional Clinical Hospital" Site 9519

Chernivtsi, , Ukraine

Site Status

Regional Communal Noncommercial Enterprise "Chernivtsi Regional Clinical Hospital" Site 9527

Chernivtsi, , Ukraine

Site Status

Public Non-Profit Enterprise "Regional Clinical Hospital under Ivano-Frankivsk Regional Council"

Ivano-Frankivsk, , Ukraine

Site Status

PNPE "Prof. O.O. Shalimov City Clinical Hospital #2" under Kharkiv City Council

Kharkiv, , Ukraine

Site Status

Public Non-Profit Enterprise under Kharkiv Regional Council "Regional Clinical Hospital"

Kharkiv, , Ukraine

Site Status

PNPE "Kyiv City Clinical Hospital #18" under the Executive Body of Kyiv City Council

Kyiv, , Ukraine

Site Status

Medical Center of the Limited Liability Company "Harmoniia Krasy"

Kyiv, , Ukraine

Site Status

Medical Center "OK!Clinic+" of the Company with Limited Liability "International Institute of Clinical Research"

Kyiv, , Ukraine

Site Status

Medical Center of the Limited Liability Company "Medical Center "CONSILIUM MEDICAL"

Kyiv, , Ukraine

Site Status

Public Non-Profit Enterprise under Kyiv Regional Council "Kyiv Regional Hospital"

Kyiv, , Ukraine

Site Status

The Municipal Enterprise "Volyn Regional Clinical Hospital" of the Volyn Regional Council

Lutsk, , Ukraine

Site Status

Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital"

Lviv, , Ukraine

Site Status

Public Non-Profit Enterprise "Odesa Regional Clinical Hospital" under Odesa Regional Council

Odesa, , Ukraine

Site Status

Public Enterprise "Poltava M.V. Sklifosovsky Regional Clinical Hospital under Poltava Regional Council"

Poltava, , Ukraine

Site Status

MNPE "Vinnytsia Regional Clinical Hospital named after M.I. Pirogov Vinnytsia Regional Council"

Vinnytsia, , Ukraine

Site Status

Communal Non-Commercial Enterprise "Vinnytsia City Clinical Hospital #1

Vinnytsia, , Ukraine

Site Status

PNPE "City Hospital of Urgent and Emergency Medical Care under Zaporizhia City Council"

Zaporizhia, , Ukraine

Site Status

MNPE "Zaporizhia Regional Clinical Hospital" of Zaporizhia Regional Council

Zaporizhia, , Ukraine

Site Status

Limited Liability Company "Medibor"

Zhytomyr, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Georgia Moldova Poland Romania Russia Serbia South Korea Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022 Feb;55(4):401-411. doi: 10.1111/apt.16753. Epub 2022 Jan 10.

Reference Type DERIVED
PMID: 35014040 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-002306-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

GB004-2101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.